PerkinElmer (NYSE:PKI) announced today that it launched the first cell painting kit as part of its PhenoVue cellular imaging reagent portfolio.
Waltham, Mass.-based PerkinElmer’s new range of reagents utilizes the company’s expertise in cellular imaging and high-content screening while working with its microplates, automation offerings and software to allow researchers to better understand diseases and develop more pinpointed therapies and drugs for treating them, according to a news release.
PhenoVue’s reagents include fluorescent organelle staining probes and dye-labeled secondary antibodies to reduce customers’ assay development time with high-content screening applications.
The system combines cell and computational biology to achieve cell painting, studying the effects of perturbagens (including chemical compounds, drugs or genes) on the behavior of cells. Cells are “painted” in the process of labeling cellular compartments with different fluorescent bioprobes to enable those areas to be quantitatively profiled.
“Researchers are using high-content screening and cell painting to make extraordinary discoveries that will help drive more innovative drugs and therapies,” PerkinElmer VP & GM of life sciences Alan Fletcher said in the release. “With the addition of our new PhenoVue cellular imaging reagents, we now offer a complete suite of high-content screening products and expert services. This will help researchers build more streamlined workflows and enjoy the convenience of working with a single, expert technology provider helping to accelerate discovery.”
Filed Under: Drug Discovery, Drug Discovery and Development
